Nam RK - Search Results

1

Next-generation prostate cancer risk calculator for primary care physicians.

Nam RK, Satkunavisam R, Chin JL, Izawa J, Trachtenberg J, Rendon R, Bell D, Singal R, Sherman C, Sugar L, Chagin K, Kattan MW. Nam RK, et al. Can Urol Assoc J. 2018 Feb;12(2):E64-E70. doi: 10.5489/cuaj.4696. Epub 2017 Dec 1. Can Urol Assoc J. 2018. PMID: 29381462 Free PMC article.

2

Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.

Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J. Yu H, et al. J Urol. 1997 Mar;157(3):913-8. J Urol. 1997. PMID: 9072598 Clinical Trial.

3

Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset.

Nam RK, Klotz LH, Jewett MA, Danjoux C, Trachtenberg J. Nam RK, et al. Br J Urol. 1998 Jan;81(1):100-4. doi: 10.1046/j.1464-410x.1998.00523.x. Br J Urol. 1998. PMID: 9467484

4

Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis.

Nam RK, Fleshner N, Rakovitch E, Klotz L, Trachtenberg J, Choo R, Morton G, Danjoux C. Nam RK, et al. J Urol. 1999 May;161(5):1521-4. J Urol. 1999. PMID: 10210387

5

Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.

Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papnastasiou PA, Jewett MA, Narod SA. Nam RK, et al. J Clin Oncol. 2000 Mar;18(5):1036-42. doi: 10.1200/JCO.2000.18.5.1036. J Clin Oncol. 2000. PMID: 10694554

6

Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up.

Vassilikos EJ, Yu H, Trachtenberg J, Nam RK, Narod SA, Bromberg IL, Diamandis EP. Vassilikos EJ, et al. Among authors: nam rk. Clin Biochem. 2000 Mar;33(2):115-23. doi: 10.1016/s0009-9120(99)00099-5. Clin Biochem. 2000. PMID: 10751589

7

Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression.

Nam RK, Elhaji Y, Krahn MD, Hakimi J, Ho M, Chu W, Sweet J, Trachtenberg J, Jewett MA, Narod SA. Nam RK, et al. J Urol. 2000 Aug;164(2):567-72. J Urol. 2000. PMID: 10893645

8

V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression.

Nam RK, Toi A, Vesprini D, Ho M, Chu W, Harvie S, Sweet J, Trachtenberg J, Jewett MA, Narod SA. Nam RK, et al. Urology. 2001 Jan;57(1):199-204. doi: 10.1016/s0090-4295(00)00928-6. Urology. 2001. PMID: 11164181

9

HPC2 variants and screen-detected prostate cancer.

Vesprini D, Nam RK, Trachtenberg J, Jewett MA, Tavtigian SV, Emami M, Ho M, Toi A, Narod SA. Vesprini D, et al. Among authors: nam rk. Am J Hum Genet. 2001 Apr;68(4):912-7. doi: 10.1086/319502. Epub 2001 Mar 14. Am J Hum Genet. 2001. PMID: 11254449 Free PMC article.

10

Radical prostatectomy as treatment for prostate cancer.

Jewett MA, Fleshner N, Klotz LH, Nam RK, Trachtenberg J. Jewett MA, et al. Among authors: nam rk. CMAJ. 2003 Jan 7;168(1):44-5. CMAJ. 2003. PMID: 12515785 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

182 results

Search Page

Filters